603077.SS
Sichuan Hebang Biotechnology Corporation Limited [603077.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
603077.SS Stock Summary
Top 10 Correlated ETFs
603077.SS
Top 10 Correlated Stocks
603077.SS
In the News
603077.SS Financial details
Company Rating
Strong Buy
Market Cap
20.59B
Income
1.4B
Revenue
8.98B
Book val./share
2.27
Cash/share
0.44
Dividend
0.05
Dividend %
1.93%
Employees
6.46K
Optionable
No
Shortable
Yes
Earnings
20 Oct 2023
P/E
14.55
Forward P/E
-
PEG
-2.62
P/S
2.26
P/B
1.03
P/C
5.39
P/FCF
-544.11
Quick Ratio
1.76
Current Ratio
2.9
Debt / Equity
0.1
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.16
EPS next Y
-
EPS next Q
-
EPS this Y
22.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
60.67%
Revenue last 5Y
16.76%
Revenue Q/Q
38.19%
EPS Q/Q
82.94%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
6%
ROE
7%
ROC
0.08%
Gross Margin
26%
Oper. Margin
18%
Profit Margin
16%
Payout
33%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.23-2.96
52W High
+18.5%
52W Low
+18.5%
RSI
53
Rel Volume
2.22
Avg Volume
66.23M
Volume
146.8M
Perf Week
0.42%
Perf Month
-1.25%
Perf Quarter
3.49%
Perf Half Y
4.41%
-
-
-
-
Beta
0.318
-
-
Volatility
0.01%, 0.04%
Prev Close
-0.42%
Price
2.37
Change
0%
603077.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.68 | 0.69 | 0.62 | 1.17 | 1.5 | |
| Net income per share | 0.04 | 0.06 | 0 | 0.36 | 0.44 | |
| Operating cash flow per share | 0.11 | 0.02 | 0.04 | 0.38 | 0.3 | |
| Free cash flow per share | 0.07 | -0.06 | 0.02 | 0.17 | 0.2 | |
| Cash per share | 0.15 | 0.09 | 0.1 | 0.21 | 0.53 | |
| Book value per share | 1.24 | 1.3 | 1.31 | 1.69 | 2.2 | |
| Tangible book value per share | 0.99 | 0.98 | 0.98 | 1.28 | 1.81 | |
| Share holders equity per share | 1.24 | 1.3 | 1.31 | 1.69 | 2.2 | |
| Interest debt per share | 0.14 | 0.22 | 0.26 | 0.17 | 0.22 | |
| Market cap | 14.22B | 12.81B | 12.11B | 28.77B | 26.44B | |
| Enterprise value | 14.04B | 14.08B | 13.41B | 28.43B | 23.67B | |
| P/E ratio | 39.16 | 24.79 | 4.16K | 9.53 | 6.95 | |
| Price to sales ratio | 2.37 | 2.15 | 2.3 | 2.92 | 2.03 | |
| POCF ratio | 15.06 | 78.65 | 32.84 | 9 | 10 | |
| PFCF ratio | 24.48 | -25.65 | 70.52 | 19.68 | 15.48 | |
| P/B Ratio | 1.3 | 1.14 | 1.09 | 2.02 | 1.38 | |
| PTB ratio | 1.3 | 1.14 | 1.09 | 2.02 | 1.38 | |
| EV to sales | 2.34 | 2.36 | 2.55 | 2.88 | 1.82 | |
| Enterprise value over EBITDA | 11.53 | 10.84 | 18.25 | 6.61 | 4.29 | |
| EV to operating cash flow | 14.87 | 86.41 | 36.36 | 8.89 | 8.95 | |
| EV to free cash flow | 24.17 | -28.18 | 78.08 | 19.45 | 13.86 | |
| Earnings yield | 0.03 | 0.04 | 0 | 0.1 | 0.14 | |
| Free cash flow yield | 0.04 | -0.04 | 0.01 | 0.05 | 0.06 | |
| Debt to equity | 0.11 | 0.17 | 0.19 | 0.1 | 0.1 | |
| Debt to assets | 0.09 | 0.13 | 0.15 | 0.08 | 0.08 | |
| Net debt to EBITDA | -0.15 | 0.97 | 1.77 | -0.08 | -0.5 | |
| Current ratio | 2 | 1.25 | 1.05 | 1.49 | 2.6 | |
| Interest coverage | 7.1 | 10.21 | 1.12 | 46.21 | 87.12 | |
| Income quality | 3.17 | 0.32 | 126.77 | 1.05 | 0.69 | |
| Dividend Yield | 0.02 | 0.01 | 0.01 | 0 | 0.01 | |
| Payout ratio | 0.7 | 0.14 | 31.88 | 0.03 | 0.05 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Intangibles to total assets | 0.19 | 0.21 | 0.2 | 0.22 | 0.17 | |
| Capex to operating cash flow | -0.38 | -4.07 | -0.53 | -0.54 | -0.35 | |
| Capex to revenue | -0.06 | -0.11 | -0.04 | -0.18 | -0.07 | |
| Capex to depreciation | -0.63 | -1.04 | -0.31 | -2.69 | -1.01 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | -0.01 | 0.04 | |
| Graham number | 1.07 | 1.32 | 0.1 | 3.69 | 4.65 | |
| ROIC | 0.02 | 0.04 | 0 | 0.19 | 0.18 | |
| Return on tangible assets | 0.03 | 0.04 | 0 | 0.21 | 0.19 | |
| Graham Net | 0.06 | -0.07 | -0.11 | 0.03 | 0.39 | |
| Working capital | 1.75B | 706.8M | 165.62M | 1.52B | 5.98B | |
| Tangible asset value | 8.73B | 8.46B | 8.38B | 10.77B | 15.75B | |
| Net current asset value | 1.43B | 460.69M | -114.95M | 1.36B | 5.38B | |
| Invested capital | 0.11 | 0.17 | 0.19 | 0.1 | 0.1 | |
| Average receivables | 1.35B | 1.18B | 1.57B | 1.82B | 2.3B | |
| Average payables | 720.12M | 856.99M | 1.01B | 1.1B | 1.52B | |
| Average inventory | 1.06B | 1.19B | 975.41M | 772.74M | 1.49B | |
| Days sales outstanding | 63.6 | 80.54 | 126.92 | 66.73 | 77.99 | |
| Days payables outstanding | 57.93 | 76.9 | 89.01 | 73.65 | 91.97 | |
| Days of inventory on hand | 82.46 | 104.34 | 54.11 | 58.11 | 101.69 | |
| Receivables turnover | 5.74 | 4.53 | 2.88 | 5.47 | 4.68 | |
| Payables turnover | 6.3 | 4.75 | 4.1 | 4.96 | 3.97 | |
| Inventory turnover | 4.43 | 3.5 | 6.75 | 6.28 | 3.59 | |
| ROE | 0.03 | 0.05 | 0 | 0.21 | 0.2 | |
| Capex per share | -0.04 | -0.08 | -0.02 | -0.21 | -0.11 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.35 | 0.29 | 0.27 | 0.19 | 0.27 | |
| Net income per share | 0.09 | 0.04 | 0.05 | 0.03 | 0.05 | |
| Operating cash flow per share | 0.09 | 0.04 | 0.05 | 0 | -0.02 | |
| Free cash flow per share | 0.05 | 0.05 | 0.03 | -0.02 | -0.05 | |
| Cash per share | 0.43 | 0.53 | 0.53 | 0.43 | 0.44 | |
| Book value per share | 2.16 | 2.19 | 2.24 | 2.22 | 2.27 | |
| Tangible book value per share | 1.76 | 1.81 | 1.85 | 1.83 | 1.87 | |
| Share holders equity per share | 2.16 | 2.19 | 2.24 | 2.22 | 2.27 | |
| Interest debt per share | 0.2 | 0.21 | 0.19 | 0.16 | 0.23 | |
| Market cap | 27.75B | 26.52B | 26.09B | 21.2B | 20.42B | |
| Enterprise value | 25.69B | 23.75B | 23.13B | 18.87B | 18.5B | |
| P/E ratio | 8.75 | 17.48 | 16.45 | 24.1 | 12.68 | |
| Price to sales ratio | 9.2 | 10.42 | 10.9 | 12.5 | 8.71 | |
| POCF ratio | 34.99 | 69.93 | 65.79 | -2.56K | -106.65 | |
| PFCF ratio | 60.98 | 64.45 | 110.05 | -99.02 | -43.27 | |
| P/B Ratio | 1.49 | 1.39 | 1.34 | 1.09 | 1.03 | |
| PTB ratio | 1.49 | 1.39 | 1.34 | 1.09 | 1.03 | |
| EV to sales | 8.52 | 9.33 | 9.66 | 11.13 | 7.89 | |
| Enterprise value over EBITDA | 28.33 | 45.82 | 46.26 | 63.75 | 38.81 | |
| EV to operating cash flow | 32.41 | 62.62 | 58.32 | -2.28K | -96.63 | |
| EV to free cash flow | 56.47 | 57.72 | 97.56 | -88.13 | -39.21 | |
| Earnings yield | 0.03 | 0.01 | 0.02 | 0.01 | 0.02 | |
| Free cash flow yield | 0.02 | 0.02 | 0.01 | -0.01 | -0.02 | |
| Debt to equity | 0.09 | 0.1 | 0.08 | 0.07 | 0.1 | |
| Debt to assets | 0.07 | 0.08 | 0.07 | 0.06 | 0.08 | |
| Net debt to EBITDA | -2.26 | -5.35 | -5.92 | -7.87 | -4.02 | |
| Current ratio | 2.49 | 2.6 | 2.77 | 3 | 2.9 | |
| Interest coverage | 59.89 | 80.28 | 33.43 | 19.63 | 32.19 | |
| Income quality | 1 | 1 | 1 | -0.04 | -0.48 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0.02 | 0.06 | 0.04 | 1.86 | 0.04 | |
| Sales general and administrative to revenue | 0.12 | -0.22 | 0.04 | -0.04 | 0.1 | |
| Research and developement to revenue | 0 | 0.02 | 0 | 0.01 | 0 | |
| Intangibles to total assets | 0.17 | 0.17 | 0.17 | 0.17 | 0.16 | |
| Capex to operating cash flow | -0.43 | 0.08 | -0.4 | 24.83 | 1.46 | |
| Capex to revenue | -0.11 | 0.01 | -0.07 | -0.12 | -0.12 | |
| Capex to depreciation | -1.42 | 0.14 | -0.66 | -0.85 | 0.58 | |
| Stock based compensation to revenue | -0.08 | 0.2 | 0 | 0.02 | -0.01 | |
| Graham number | 2.11 | 1.46 | 1.51 | 1.12 | 1.53 | |
| ROIC | 0.04 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Return on tangible assets | 0.04 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Graham Net | 0.36 | 0.39 | 0.43 | 0.38 | 0.37 | |
| Working capital | 5.15B | 5.98B | 6.15B | 6.22B | 6.78B | |
| Tangible asset value | 15.2B | 15.75B | 16.14B | 15.95B | 16.33B | |
| Net current asset value | 4.75B | 5.38B | 5.74B | 5.64B | 5.91B | |
| Invested capital | 0.09 | 0.1 | 0.08 | 0.07 | 0.1 | |
| Average receivables | 3.22B | 3.1B | 2.62B | 2.26B | 2.23B | |
| Average payables | 1.6B | 1.72B | 1.84B | 1.84B | 1.92B | |
| Average inventory | 1.21B | 1.68B | 2.21B | 2.88B | 3.71B | |
| Days sales outstanding | 101.92 | 98.5 | 92.23 | 109.64 | 92.05 | |
| Days payables outstanding | 76.29 | 96.5 | 91.52 | 124.85 | 100.4 | |
| Days of inventory on hand | 63.18 | 106.71 | 119.06 | 227.12 | 204.14 | |
| Receivables turnover | 0.88 | 0.91 | 0.98 | 0.82 | 0.98 | |
| Payables turnover | 1.18 | 0.93 | 0.98 | 0.72 | 0.9 | |
| Inventory turnover | 1.42 | 0.84 | 0.76 | 0.4 | 0.44 | |
| ROE | 0.04 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Capex per share | -0.04 | 0 | -0.02 | -0.02 | -0.03 |
603077.SS Frequently Asked Questions
What is Sichuan Hebang Biotechnology Corporation Limited stock symbol ?
Sichuan Hebang Biotechnology Corporation Limited is a CN stock and trading under the symbol 603077.SS
What is Sichuan Hebang Biotechnology Corporation Limited stock quote today ?
Sichuan Hebang Biotechnology Corporation Limited stock price is $2.37 today.
Is Sichuan Hebang Biotechnology Corporation Limited stock public?
Yes, Sichuan Hebang Biotechnology Corporation Limited is a publicly traded company.
Company Profile
- Volume Average 66.23M
- Market Capitalization 20.59B
- Employee 6.46K
- CEO Ms. Huirong Yang
- Headquarters Chengdu,CN
- IPO Date 2012-07-31
-
Website
https://www.hebang.cn 
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company also provides original glass and smart glass, special glass, low-e coated glass, and photovoltaic packaging materials and products, as well as photovoltaic glass and module products. In addition, it engages in the supply of oil and gas. The company was formerly known as SichuanHebang Biotechnology Co.,Ltd. and changed its name to Sichuan Hebang Biotechnology Corporation Limited in April 2021. Sichuan Hebang Biotechnology Corporation Limited was founded in 2002 and is based in Chengdu, China.
